Olema Pharmaceuticals (OLMA) late Monday disclosed plans for two prospective securities offerings, including up to $200 million of its common or preferred stock, warrants to buy shares or debt securities.
The company, which is developing cancer therapies for women, also plans potential sale of up to $150 million of its common stock through a sales agreement.
Olema said net proceeds from any future offering would be used for working capital, research and development expenses or other general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.